The ApoC3 assay kit plays a key role in disease diagnosis, risk assessment, treatment monitoring, and drug development by detecting the content of ApoC3 in serum or plasma. The specific application scope is as follows:
1. Disease diagnosis and auxiliary diagnosis
Mechanism of hypertriglyceridemia (HTG): ApoC3 inhibits lipoprotein lipase (LPL) activity, leading to triglyceride (TG) metabolic disorders. Application: Assist in the diagnosis of familial hypertriglyceridemia (FHTG) and assess the risk of cardiovascular disease (CVD) in patients with HTG.
The mechanism of atherosclerotic cardiovascular disease (ASCVD): The increase of ApoC3 level is related to the small and dense particles of low-density lipoprotein cholesterol (LDL-C) and the impairment of high-density lipoprotein cholesterol (HDL-C) function.
Application: Evaluate CVD risk, especially in patients with mixed dyslipidemia;
; Monitor changes in ApoC3 after statin therapy and predict therapeutic efficacy. The mechanism of metabolic syndrome (MetS): ApoC3 levels are associated with MetS core features such as insulin resistance, obesity, and hypertension.Application: Assist in diagnosing MetS and evaluating the degree of metabolic disorders;
; Monitor the effectiveness of lifestyle interventions or medication treatments.Mechanism of pancreatitis: Severe HTG (TG>1000 mg/dL) is an important trigger for acute pancreatitis, and elevated ApoC3 levels are associated with increased risk of pancreatitis.
.Application: Screening high-risk populations for HTG related pancreatitis;
; Monitor blood lipid changes in patients with pancreatitis and guide treatment.Liver disease mechanism: The liver is the main synthesis site of ApoC3, and liver disease (such as non-alcoholic fatty liver disease NAFLD) can lead to abnormal levels of ApoC3.
.Application: Assist in the diagnosis of NAFLD and evaluate the degree of liver injury;
; Monitor the metabolic improvement after liver disease treatment.II. Risk stratification of cardiovascular disease
Optimize risk assessment model: combine LDL-C, HDL-C, non-HDL-C and other indicators to improve the accuracy of CVD risk prediction.
. Predicting adverse events: Predicting the risk of major adverse cardiovascular events (MACE) in ASCVD patients, providing a basis for clinical decision-making.III. diabetes and its complication management
Blood glucose control and complication risk: ApoC3 level is related to blood glucose control and microvascular complications (such as diabetes nephropathy) in patients with type 2 diabetes (T2DM). Application: Evaluating the risk of dyslipidemia in T2DM patients; Monitor the progress of complications of diabetes.
IV. Drug Development and Individualized Treatment
Evaluation of the regulatory effect of antisense oligonucleotides (such as Volanesorsen), PCSK9 inhibitors, and other drugs on ApoC3 levels in the development of new lipid-lowering drugs.
. Screening targeted therapeutic drugs targeting ApoC3. Individualized treatment guidance adjusts the dosage of lipid-lowering drugs (such as statins and betas) based on ApoC3 levels. Optimize the combination therapy regimen to improve treatment efficacy.Fifth, screening and health management of high-risk populations
Screening of high-risk populations for HTG, MetS, and CVD to achieve early intervention.
. Evaluate the genetic risk of patients with familial dyslipidemia.Health check ups are used as supplementary indicators for lipid profile testing to comprehensively evaluate lipid metabolism status.
. Provide personalized health advice to reduce the risk of diseases.VI. Technical Advantages and Clinical Value
Technical Advantages High Sensitivity: The detection limit is as low as 0.1 mg/dL, suitable for micro sample analysis.
.Multi party legal compatibility: Supports various technical platforms such as immunoturbidimetry and enzyme-linked immunosorbent assay (ELISA).
. Wide range of sample types: suitable for serum, plasma, tissue homogenate, cell culture supernatant, etc. Clinical value risk prediction: ApoC3 level is an independent CVD risk predictor independent of traditional lipid indicators such as LDL-C and HDL-C.Mechanism exploration: providing key data for the molecular mechanism research of lipid metabolism disorders.
.source:http://en.zjikon.com/news1076270.html